Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezvilutamide + ADT in Adjuvant AR+ Salivary Duct Carcinoma
NCT06348264Phase 2Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Oct 2024
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezvilutamide in salivary duct carcinoma (SDC), sponsored by Peking University First Hospital. Started Oct 2024; status: recruiting.
02
Drugs
rezvilutamide
03
Conditions
salivary duct carcinoma (SDC)
Beyond the preview
Go deeper on NCT06348264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06348264.